AIDS RESEARCH AND HUMAN RETROVIRUSES
Volume 30, Number 6, 2014

DOI: 10.1089/aid.2013.0255

HIV-Associated Anemia After 96 Weeks on Therapy: Determinants Across Age Ranges in Uganda and Zimbabwe

Devan Jaganath,[1] A. Sarah Walker,[2] Francis Ssali,[3] Victor Musiime,[3] Francis Kiweewa,[3] Cissy Kityo,[3] Robert Salata,[4] and Peter Mugyenyi,[3] for the DART and ARROW Trials

Abstract

Given the detrimental effects of HIV-associated anemia on morbidity, we determined factors associated with anemia after 96 weeks of antiretroviral therapy (ART) across age groups. An HIV-positive cohort ($n = 3{,}580$) of children age 5–14, reproductive age adults 18–49, and older adults ≥ 50 from two randomized trials in Uganda and Zimbabwe were evaluated from initiation of therapy through 96 weeks. We conducted logistic and multinomial regression to evaluate common and differential determinants for anemia at 96 weeks on therapy. Prior to initiation of ART, the prevalence of anemia (age 5–11 < 10.5 g/dl, 12–14 < 11 g/dl, adult females < 11 g/dl, adult males < 12 g/dl) was 43%, which decreased to 13% at week 96 ($p < 0.001$). Older adults had a significantly higher likelihood of anemia compared to reproductive age adults (OR 2.60, 95% CI 1.44–4.70, $p = 0.002$). Reproductive age females had a significantly higher odds of anemia compared to men at week 96 (OR 2.56, 95% CI 1.92–3.40, $p < 0.001$), and particularly a greater odds for microcytic anemia compared to males in the same age group ($p = 0.001$). Other common factors associated with anemia included low body mass index (BMI) and microcytosis; greater increases in CD4 count to week 96 were protective. Thus, while ART significantly reduced the prevalence of anemia at 96 weeks, 13% of the population continued to be anemic. Specific groups, such as reproductive age females and older adults, have a greater odds of anemia and may guide clinicians to pursue further evaluation and management.

Introduction

Anemia is estimated to affect 1.62 billion people, or almost a quarter of the world's population.[1] It is a common complication of HIV infection, with etiologies including HIV infection itself, gastrointestinal and menstrual blood loss, opportunistic infections, neoplasms, medications, and malnutrition.[2–4] In sub-Saharan Africa, conditions including malaria, hookworm, tuberculosis, and hemoglobinopathies also contribute to anemia.[2] HIV-associated anemia has considerable consequences, including a worse quality of life and increased mortality, independent of markers such as CD4 or viral load.[2,5–7]

Antiretroviral therapy (ART) reduces the prevalence of HIV-related anemia.[8–11] However, studies suggest over 30% prevalence of anemia even while on ART, and it continues to predict mortality and poor quality of life.[2,4,8–10,12] The studies have been largely from developed countries and have focused on early determinants of anemia, primarily among individuals of reproductive age. With greater access to ART in sub-Saharan Africa, the HIV population has a wider age range and has been on therapy for several years. As HIV-infected individuals transition through life stages, it is important to understand the similarities and differences of risk factors for anemia. Utilizing two large pediatric and adult trials in Uganda and Zimbabwe, we investigated the prevalence and risk factors for HIV-related anemia after 96 weeks on ART, among children 5–14, reproductive age adults, and older adults greater than 50 years old.

Materials and Methods

Anemia was evaluated among participants in the Delivery of Antiretroviral Therapy in Africa (DART) (ISRCTN 13968779) and Antiretroviral Research for Watoto (ARROW) (ISRCTN 24791884) trials in three sites in Uganda and one in Zimbabwe.[13,14] The primary aim of these trials was a randomized comparison of clinically driven monitoring (CDM)

[1]David Geffen School of Medicine at UCLA, Los Angeles, California.
[2]MRC Clinical Trials Unit, London, United Kingdom.
[3]Joint Clinical Research Centre, Kampala, Uganda.
[4]Division of Infectious Diseases, Case Western Reserve University, Cleveland, Ohio.

to laboratory with clinical monitoring (LCM) of ART. The primary efficacy outcome was new nonrecurrent WHO stage 4 clinical events and/or death; the primary toxicity outcome was serious adverse events (SAEs) in DART and Grade 3/4 AEs in ARROW. Neither trial found significant differences in toxicity outcomes between CDM and LCM,[13,14] so data from both randomized groups were pooled for this analysis.

We sought to investigate anemia after 96 weeks on therapy, and therefore included DART and ARROW participants who were alive and in follow-up 96 weeks after ART initiation. Participants were ART naive prior to enrollment, except for past exposure to prevent mother-to-child transmission (PMTCT) of HIV. For the DART study, adults (18 years or older) were eligible if they had a CD4 count <200 cells/mm^3 and WHO stage 2 or greater. For the ARROW study, children 5–14 were eligible if they met WHO 2006 pediatric guidelines for ART (CD4 <200 cells/mm^3 and/or WHO stage 3 or 4 disease).[15] Younger children face unique factors for anemia including early childhood infections, PMTCT exposure, and birth complications that we were unable to compare across groups, and thus were excluded from the analysis. Exclusion criteria in both trials included signs of an acute infection, contraindications to take ART due to concomitant medications or abnormal laboratory values, or pregnancy/breastfeeding in women.

After enrollment, participants were initiated on ART. In 2003–2004, DART participants received zidovudine/lamivudine plus tenofovir, abacavir, or nevirapine, with 600 participants randomized to abacavir vs. nevirapine.[16] From 2007–2008, ARROW participants received one of two regimens: abacavir/lamivudine plus a nonnucleoside reverse transcriptase inhibitor (NNRTI, nevirapine or efavirenz) or a four-drug regimen of abacavir/lamivudine, zidovudine, and an NNRTI. After 36 weeks, ART regimens of those in the four-drug regimen were reduced to three drugs, removing either zidovudine or the NNRTI, as per the ARROW trial protocol.[14]

Follow-up included symptom assessment every 4–6 weeks and clinical examination and lymphocytic (CD4/CD8) and hematological testing every 12 weeks. Whereas results from LCM participants were given to clinicians, results for CDM participants were given upon request to inform clinical management (except for CD4 count, which was never returned) or if there was grade 4 toxicity that had not already been requested (protocol safety criteria).[13,14]

Anemia in this analysis was defined according to WHO guidelines, adjusted for African ethnicity.[17] For adults 15 years of age or older, anemia was defined as hemoglobin <12.0 g/dl in males and <11.0 g/dl in females. Children 5–11 years were considered anemic if they had a hemoglobin <10.5 g/dl, and for children 12–14 years, anemia was a hemoglobin <11.0 g/dl. Mild anemia was defined as 10.0–11.9 g/dl in male and 10.0–10.9 g/dl in female adults 15 years and older, 10–10.4 g/dl in children 5–11 years, and 10–10.9 g/dl in children 12–14 years. Moderate anemia was defined as 7.0–9.9 g/dl, and severe anemia was less than 7.0 g/dl, in all ages. Microcytosis in adults was defined as a mean corpuscular volume (MCV) less than 80 fl and macrocytosis if greater than 100 fl. For children ages 5–11 years, the normal MCV range was 70–92 fl, and for children 12–14 the MCV normal range was 76–102 fl. Microcytic, normocytic, or macrocytic anemia was defined as anemia with microcytosis, normocytosis, or macrocytosis, respectively. To assess nutritional status, low body mass index (BMI) was defined as a BMI <18.5 kg/m^2 for adults, whereas for children, it was defined as a BMI-for-age Z score (UK) of ≤ 2.

The cohort was stratified into three age groups for analysis: children ages 5–14 years, reproductive age adults 18–49 years, and older adults greater than 50 years. Wilcoxon signed-rank test and McNemar's test were used to compare pre-ART and week 96 variables. Therefore, by definition, analysis included those with follow-up at 96 weeks [639 of 667 (96%) in ARROW age <14, and 3,006 of 3,316 (91%) in DART]. Of these individuals, hemoglobin measurements were available for 635 (99%) in ARROW and 2,945 (98%) in DART. Simple and multiple logistic regression and multinomial logistic regression were used to identify risk factors for anemia at week 96 from pre-ART and week 96 variables. Variables were included in the multiple logistic models if the p-value was <0.20 on univariate testing. Heterogeneity of risk factors between age groups was evaluated by assessing the significance ($p<0.05$) of the interaction term between age group and the given risk factor. Hosmer–Lemeshow goodness of fit testing with 10 quantiles was used to evaluate the final model.

The DART and ARROW studies received ethical approval from their respective institutions in Uganda, Zimbabwe, and the United Kingdom. This substudy analysis was also reviewed and approved by the Institutional Review Board of the Joint Clinical Research Centre (JCRC) and the Uganda National Council for Science and Technology (UNCST).

Results

A total of 3,580 HIV-infected children and adults were included in the analysis, of whom 635 (18%) were children aged 5–14 years, 2,750 (77%) adults aged 18–49 years, and 195 (5%) adults older than 50 years. Characteristics at initiation of ART and week 96 are summarized in Table 1. CD4 count improved significantly in all age groups, from an overall median of 98 cells/mm^3 pre-ART to 271 cells/mm^3 at week 96 ($p<0.001$), as did nutritional status with an overall reduction in those subjects with low BMI from 17% to 5% ($p<0.001$). Prior to initiation of ART, 1,527 individuals (43%) had anemia, including 217 (34%) children, 1,228 (45%) reproductive age adults, and 82 (42%) older adults. Among those with anemia, 451 (30%) had microcytic anemia, 1,009 (66%) had normocytic anemia, and 67 (4%) had macrocytic anemia. At 96 weeks, there was a significant reduction in the prevalence of anemia to 482 cases (13%), including 44 children (7%), 407 (15%) reproductive age adults, and 31 (16%) older adults ($p<0.001$ for all groups and overall).

Among those with anemia at 96 weeks, 56 cases (12%) were microcytic, 250 (52%) were normocytic, and 174 (36%) were macrocytic. Severe anemia (<7 g/dl) was rare, with 2 cases pre-ART initiation and 11 cases at week 96 ($<1\%$). Iron use was minimal in this cohort, with 24 individuals ($<1\%$) taking iron supplements between weeks 94 and 98. Similarly, there were limited cases of malaria [clinical or blood slide confirmed, $n=28$ (1%)], acute febrile illness ($n=2$, $<1\%$), or WHO stage 3/4 events ($n=14$, $<1\%$) between weeks 94 and 98. WHO 3/4 events included HIV

Table 1. Comparison of Pre-Antiretroviral Therapy and Week 96 Characteristics (N = 3,580)

Characteristic N (%) or median (IQR)	*Age 5–14* (n = *635*)		*Age 18–49* (n = *2750*)		*Age 50+* (n = *195*)		*Total*	
	Pre-ART	*Week 96*	*Pre-ART*	*Week 96*	*Pre-ART*	*Week 96*	*Pre-ART*	*Week 96*
Female	218 (50)		1,815 (66)		101 (52)		2234 (62)	
BMI (kg/m^2)	15.0 (14.1, 15.8)	16.0 (15.2, 17.3)[a]	21.2 (19.2, 23.5)	23.5 (21.1, 26.4)[a]	22.1 (19.8, 25.0)	23.8 (21.2, 26.6)[a]	20.5 (17.7, 23.1)	22.5 (19.4, 25.7)[a]
Low BMI	99 (16)	13 (2)[a]	469 (17)	139 (5)[a]	23 (12)	9 (5)[b]	591 (17)	161 (5)
CD4 (cells/mm^3)	251 (95, 392)	630 (444, 916)[a]	87 (32, 140)	243 (170, 327)[a]	96 (47, 147)	231 (164, 327)[a]	98 (38, 159)	271 (182, 392)[a]
350+	189 (30)	530 (84)		558 (20)		38 (16)	189 (5)	1,126 (32)
200–349	181 (29)	60 (9)		1231 (45)		84 (43)	181 (5)	1,375 (39)
100–199	105 (17)	22 (3)	1188 (43)	688 (25)	92 (47)	54 (28)	1,385 (39)	764 (21)
0–99	160 (25)	21 (3)	1562 (57)	262 (10)	103 (53)	18 (9)	1,825 (51)	301 (8)
Hemoglobin (g/dl)	11.1 (10.2, 11.9)	12.2 (11.4, 12.9)[a]	11.4 (10.3, 12.7)	12.8 (11.8, 13.9)[a]	11.6 (10.6, 12.7)	12.9 (11.9, 13.9)[a]	11.4 (10.3, 12.5)	12.6 (11.7, 13.7)[a]
MCV (fl)	80.0 (75.0, 83.8)	89.1 (84.0, 94.7)[a]	85.5 (80.0, 91.0)	101.0 (94.0, 108.0)[a]	86.4 (83.0, 92.0)	103.0 (96.0, 110.0)[a]	84.5 (79.0, 90.0)	99.0 (91.0, 107.0)[a]
Microcytosis	56 (9)	10 (2)	691 (25)	122 (4)	34 (17)	8 (4)	781 (22)	140 (4)
Normocytosis	565 (89)	418 (66)	1,931 (70)	1,195 (44)	148 (76)	67 (34)	2,644 (74)	1,680 (47)
Macrocytosis	14 (2)	207 (33)	128 (5)	1,431 (52)	13 (7)	120 (62)	155 (4)	1,758 (49)
Anemic	217 (34)	44 (7)[a]	1,228 (45)	407 (15)[a]	82 (42)	31 (16)[a]	1,527 (43)	482 (13)[a]
Mild	80 (13)	23 (4)	639 (23)	249 (9)	53 (27)	22 (11)	772 (22)	294 (8)
Moderate	137 (22)	21 (3)	587 (21)	148 (5)	29 (15)	8 (4)	753 (21)	177 (5)
Severe	0	0	2 (< 1)	10 (< 1)	0	1 (< 1)	2 (< 1)	11 (< 1)
Zidovudine	437 (69)	210 (33)[a]	2,750 (100)	2,416 (88)[a]	195 (100)	168 (86)[a]	3,382 (95)	2,794 (78)[a]
Cotrimoxazole	617 (97)	590 (93)[b]	1,743 (63)	1,551 (56)[a]	109 (56)	110 (56)	2,469 (69)	2,251 (63)[a]
Multivitamins	364 (57)	399 (63)[a]	0	45 (2)[a]	0	3 (2)	364 (10)	447 (12)[a]

[a]Difference between week 96 and pre-ART $p < 0.001$.
[b]Difference between week 96 and pre-ART $p = 0.001$.
Pairwise comparison using Wilcoxon signed-rank test and McNemar's test for categorical and continuous variables, respectively.
ART, antiretroviral therapy; BMI, body mass index; MCV, mean corpuscular volume.

Table 2. Multiple Logistic Regression for Risk Factors of Anemia at Week 96

	OR	*95% CI*	p-*value*
Age group			
Child	1.91	1.01, 3.62	0.05
Reproductive age	1.00		
Older adult	2.60	1.44, 4.70	0.002
Female			
Female and child	0.89	0.46, 1.70	0.72
Female and reproductive age	2.40	1.82, 3.18	<0.001
Female and older age	0.66	0.29, 1.53	0.34
Prior to initiation of ART			
Low baseline BMI	0.96	0.71, 1.29	0.78
CD4 (cells/mm^3)			
350+	0.50	0.22, 1.16	0.11
200–349	0.79	0.36, 1.71	0.54
100–199	1.00		
0–99	0.81	0.65, 1.01	0.06
Anemia pre-ART	3.30	2.65, 4.11	<0.001
Microcytosis	1.51	1.18, 1.92	0.001
Week 96			
Low BMI	3.47	2.25, 5.34	<0.001
CD4 Change (per 100 cells/mm^3) from baseline	0.87	0.81, 0.94	<0.001
Microcytosis	2.76	1.84, 4.15	<0.001
Zidovudine use[a]	1.10	0.81, 150	0.52
Cotrimoxazole Use[a]	0.91	0.73, 1.14	0.42
WHO stage 3/4 event[a]	1.80	0.50, 6.51	0.37

[a]Defined if taken or occurred between weeks 94 and 98.
Hosmer–Lemeshow goodness of fit $p=0.27$.

wasting, cryptococcosis, cryptosporidiosis, esophageal candidiasis, and extrapulmonary TB.

Univariate testing was conducted to suggest possible risk factors for anemia after 96 weeks on therapy (Supplementary Table S1; Supplementary Data are available online at www.liebertpub.com/aid). Prior to initiation of ART, female gender, a low BMI, anemia at initiation, and microcytosis were associated with anemia, while higher CD4 counts protected against the development of anemia (Supplementary Table S1). Characteristics at week 96 associated with anemia included low BMI, microcytosis, zidovudine use, pregnancy, and having a WHO stage 3/4 event. Cotrimoxazole use and higher pre-ART CD4 were associated with lower odds of anemia.

In the multiple logistic model (Tables 2 and 3), older adults had greater than twice the odds of anemia compared to reproductive age individuals (OR 2.63, 95% CI 1.45–4.78, $p=0.001$). There was significant heterogeneity of the impact of gender ($p<0.001$), with females in the reproductive age group having an increased likelihood of anemia (OR versus males 2.56, 95% CI 1.92–3.40, $p<0.001$), whereas odds were similar in males and females in the other groups. While low BMI at initiation of ART was not a significant risk factor, individuals with a low BMI at week 96 had over three times the likelihood of anemia (OR 3.47, 95% CI 2.25–5.34, $p<0.001$). There appeared to be increased odds in adults compared to children, but heterogeneity was not statistically significant ($p=0.42$). Greater CD4 increases from pre-ART baseline were associated with reduced likelihood of anemia (OR 0.87 per every 100 cells/mm^3 increase from week 0 to 96, 95% CI 0.81–0.94, $p<0.001$), and the effect was greatest among reproductive age adults (heterogeneity $p=0.002$). Zidovudine use did not have a significant effect overall, but odds of anemia appeared to be marginally increased among

Table 3. Multiple Logistic Regression by Age Group for Risk Factors of Anemia at Week 96

	Children			*Reproductive age*			*Older adults*			
	OR	*95% CI*	p-*value*	*OR*	*95% CI*	p-*value*	*OR*	*95% CI*	p-*value*	p *value*[a]
Female	0.81	0.42, 1.54	0.51	2.56	1.92, 3.40	<0.001	0.74	0.30, 1.79	0.50	<0.001
Prior to initiation of ART										
Low baseline BMI	0.61	0.22, 1.70	0.35	1.03	0.74, 1.43	0.85	0.94	0.26, 3.40	0.93	0.47
CD4 (cells/mm^3)										0.89
350+	0.55	0.20, 1.50	0.24							
200–349	0.81	0.31, 2.11	0.67							
100–199	1.00			1.00			1.00			
0–99	1.07	0.41, 2.77	0.90	0.80	0.63, 1.02	0.07	1.03	0.43, 2.45	0.95	
Anemia pre-ART	1.57	0.81, 3.06	0.18	3.64	2.85, 4.64	<0.001	3.68	1.46, 9.29	0.01	0.13
Microcytosis	2.29	0.94, 5.57	0.07	1.47	1.13, 1.90	0.004	1.41	0.44, 4.56	0.56	0.55
Week 96										
Low BMI	1.15	0.13, 10.6	0.90	3.39	2.14, 5.36	<0.001	5.84	0.95, 36.08	0.06	0.42
CD4 change (per 100 cells/mm^3) from baseline	0.95	0.90, 1.00	0.05	0.76	0.68, 0.84	<0.001	0.94	0.64, 1.37	0.73	0.002
Microcytosis	4.04	0.79, 20.53	0.09	2.77	1.79, 4.28	<0.001	1.40	0.18, 11.06	0.75	0.54
Zidovudine use[b]	1.91	1.00–3.63	0.05	0.87	0.62, 1.23	0.43	3.34	0.62, 18.24	0.16	0.06
Cotrimoxazole Use[b]	0.95	0.28, 3.28	0.94	0.90	0.71, 1.14	0.39	0.63	0.26, 1.53	0.31	0.88

[a]Heterogeneity *p*-value evaluating the interaction between the risk factor and age group.
[b]Defined if taken or occurred between weeks 94 and 98.
Hosmer–Lemeshow goodness of fit (children $p=0.60$, reproductive $p=0.20$, older $p=0.62$).

Table 4. Multinomial Logistic Regression on the Effects of Gender and Age on Anemia Subtype

	Microcytic anemia (56 cases)			*Normocytic anemia (250 cases)*			*Macrocytic anemia (174 cases)*		
	OR[a]	*95% CI*	p-*value*	*OR*	*95% CI*	p-*value*	*OR*	*95% CI*	p-*value*
Child female vs. male	0.44	0.04, 4.96	0.51	0.85	0.41, 1.77	0.67	0.57	0.13, 2.42	0.45
Reproductive age female vs. male	33.27	4.54, 243.72	0.001	3.25	2.22, 4.77	<0.001	1.79	1.22, 2.64	0.003
Older female vs. male[b]				0.76	0.18, 3.10	0.70	0.51	0.17, 1.48	0.22

[a]Adjusted for CD4 category and low BMI at week 96.
[b]Only two older women (0 men) had microcytic anemia at week 96.

children ($p=0.05$). There was no effect of cotrimoxazole on anemia overall or in any subgroup ($p=0.42$).

Given the interaction between gender and age group, we explored the impact of age and gender on subtypes of anemia at week 96 (Table 4). Multinomial logistic regression found that compared to males in the same age strata, reproductive age females had significantly higher odds of microcytic anemia (OR 33.27, 95% CI 4.54–243.72, $p=0.001$), adjusted for low BMI and CD4. They also had a significantly greater odds of both normocytic ($p<0.001$) and macrocytic ($p=0.003$) anemia compared to reproductive age males. There were no other significant differences between males and females on subtype of anemia among children or older adults. In a separate multivariable logistic regression analysis among women of reproductive age, we also found that current pregnancy was associated with a significant 2.5 times greater odds of anemia at week 96 (data not shown).

Discussion

HIV-associated anemia is a multifactorial disease that continues to complicate care despite greater access to therapy. By exploring the burden and risk factors for HIV-associated anemia after 96 weeks on therapy, we evaluated the similarities and differences across different life stages to illuminate potential relationships that can guide evaluation and management of HIV-positive patients in resource-limited settings similar to Uganda and Zimbabwe.

Prior to starting therapy, there was a high prevalence of anemia at 43%. This is consistent with other studies in sub-Saharan Africa that demonstrate a pre-ART prevalence of anemia of 63–77.4%.[8,11] This reflects low-grade anemia, with only two cases of severe anemia at initiation. After 96 weeks on ART, the prevalence significantly decreased to 13%, and all age groups had increases in hemoglobin. This is similar to HIV-negative individuals in related settings; a study in Rwanda found that HIV-negative women had an anemia prevalence of 8%.[18] Given there are an estimated 767,292 individuals currently on therapy in Uganda and Zimbabwe, 13% still represents almost 100,000 individuals and a continued burden among this population.[19]

In evaluating the possible factors associated with anemia, there were few acute clinical events that occurred around week 96, including malaria, WHO stage 3 or 4 events, or acute febrile illness. Older individuals had over twice the odds of anemia compared to reproductive age individuals, adjusted for extent of HIV infection, nutritional status, and therapy. In sub-Saharan Africa, there are an estimated 3 million individuals greater than 50 years old living with HIV/AIDS.[20] HIV infection and/or the effects of therapy may accelerate the onset of comorbidities associated with aging.[21] Regardless of HIV infection, older individuals also have an increased risk of anemia, as a consequence of other comorbidities, increased inflammation, and reduced erythropoietic function.[22] In our sample, older adults represented only 5% of the sample, and thus definitive conclusions are limited. However, with a rising number of HIV-infected individuals entering into older ages, it is important to understand that they face a greater likelihood of anemia while on therapy that may guide further management by practitioners.

HIV infection can promote malnutrition via opportunistic infections and chronic inflammation, while malnutrition can dysregulate immune function.[23] We found that independent of HIV disease extent, low BMI was associated with over three times the odds of anemia at week 96, especially among adults. While there was no significant effect within the pediatric subgroup, the power to detect effects within the different subgroups was limited. Moreover, microcytosis prior to ART initiation and at week 96 was associated with anemia among children, and may reflect a more child-specific mechanism of malnutrition through iron deficiency. Several studies show a high burden of iron deficiency anemia in HIV-infected children, with benefits after supplementation.[24–26]

The association of hemoglobin, CD4, and progression of HIV infection is well established.[10,11,27,28] Consistent with these findings, we found lower odds of anemia in those with higher increases in CD4 counts from pre-ART baseline. Surprisingly, we found that those with pre-ART CD4 less than 100 cells/mm^3 also had a marginal level of protection. This could be due to a survival bias; those who had a low CD4 count and survived to 96 weeks may have had a good response to ART, whereas those with low CD4 count who died in the first 96 weeks were not included in our analysis by design. This is supported by another substudy from the DART and ARROW trials, which found mortality rates of 3.3% of children and 5.4% of adults in the first year after initiation of therapy, and demonstrated that low hemoglobin levels were an independent predictor of mortality early after initiation of therapy.[29] Hemoglobin has been suggested as a marker of virological failure,[30,31] and thus patients with anemia may need to be closely evaluated for signs of treatment failure.

While zidovudine-based regimens are associated with an overall increase in hemoglobin levels,[28,32] macrocytic anemia is a well-known complication.[8,33] This is reflected in the large increase in prevalence of macrocytosis, from 4% to 49% overall. Although we did not find an overall effect of zidovudine use, children on zidovudine had a marginally increased association with anemia. However, it is important

to note that children did not have episodes of severe anemia,[14] and therefore any impact of zidovudine is restricted to low-grade anemia. In addition, recent WHO treatment guidelines do not recommend zidovudine in first line therapy for adults, and thus future studies may demonstrate a further reduction in anemia at 96 weeks of therapy with newer regimens.[34]

In comparing the association of anemia across age groups, we found a large and specific effect among women of reproductive age. Several cohorts have found HIV-infected women have a greater risk of anemia compared to both HIV-negative women and HIV-positive men, and anemia is an independent predictor of mortality.[7,10,35–38] The cause of this increased risk is likely due to menstruation and pregnancy, associated with blood loss and greater micronutrient requirements including iron.[39–41] Consistent with this, we found that reproductive age women, but not females in the other age groups, had a significantly increased association of microcytic anemia compared to males. Women also had increased odds of normocytic anemia, which may reflect blood loss or a combination effect of microcytic and macrocytic anemia from zidovudine and/or cotrimoxazole use. Increased odds of macrocytic anemia in this age range may be due to differences in adherence,[42] but warrants further investigation. As HIV-infected girls enter into adulthood, they enter a specific period where they have a significantly greater likelihood of anemia and may benefit from micronutrient supplementation.[43] At the same time, there is evidence that HIV-infected women enter menopause at an earlier age,[44] when these effects would be reduced and other factors of older age may take precedence as a basis for anemia.

There are several advantages to our study in contributing to our understanding of HIV-associated anemia. Studies on this topic have been conducted largely in developed countries, or have been in adults or pregnant women. In our analysis, we have included a large sample from sub-Saharan Africa, encompassing a wide age range to allow for stratification and comparison of groups. The period of 96 weeks was chosen primarily because past studies have focused on the first year on therapy. However, several studies have shown that there may be initial effects from therapy or continued effects from HIV infection.[5,8,29] We sought to describe factors associated with anemia at a later time point to reflect a population in a resource-limited setting that had survived and had been on therapy for a prolonged period.

At the same time, there were limitations to our analysis that suggest areas for further exploration. We would have benefited from greater etiological testing, including red blood cell indices, iron studies, assessment for helminthic infection diagnosis, and evaluation of hemoglobinopathies. We also did not have HIV-negative cases that would have allowed us to compare the 13% prevalence of anemia to the background population. While the cohort we created deliberately included those who were alive at week 96, this excluded those who died prior to this period; results are therefore generalizable primarily to a population that responds to ART and does not experience early mortality.

The cohort included individuals who had advanced disease; although recent guidelines have expanded to those with CD4 ≤ 500 cell/mm^3,[34] experience in high-income countries suggests that late presenters will continue to contribute a large minority.[45] Though severe anemia may have been a more specific outcome, this represented only a small percentage of our sample and power was too low to attempt this. While we benefited from data from two large randomized trials conducted by similar trials groups, there are limitations in pooled analysis, including differences in the period of evaluation, staff, and therapy given between the two studies. However, both trials recruited adults and children from identical centers in Uganda and Zimbabwe, so underlying populations should have been similar. While there may be differences between geographic sites, inclusion criteria and overall care were standardized among all centers.

While ART improves anemia status in HIV-infected individuals in resource-limited settings, there are other factors that contribute to anemia across age groups. As HIV-infected individuals age, greater investigation of anemia status may be required during specific periods, including reproductive age females and adults as they enter older age.

Acknowledgments

All authors greatly contributed to the design of this pooled substudy. D.J. performed the analysis and manuscript preparation, with critical support and editing from the other authors. A.S.W., F.S., V.M., F.K., C.K., and P.M. contributed greatly to the design and conduct of the DART and ARROW studies. The authors thank all patients and staff in the DART and ARROW trials. For the design and analysis, we thank Dr. Harriet Namata, Joshua Kayiwa, and Nelson Kakande for their invaluable guidance.

DART and ARROW Committee Members: DART Trial Steering Committee: I. Weller (Chair), A. Babiker (Trial Statistician), S. Bahendeka, M. Bassett, A. Chogo Wapakhabulo, J. Darbyshire, B. Gazzard, C. Gilks, H. Grosskurth, J. Hakim, A. Latif, C. Mapuchere, O. Mugurungi, P. Mugyenyi; Observers: C. Burke, S. Jones, C. Newland, S. Rahim, J. Rooney, M. Smith, W. Snowden, J-M. Steens. DART Project Leaders: E. Katabira, C. Kityo, P. Munderi, A. Reid, D.M. Gibb. ARROW Trial Steering Committee: I. Weller (Chair), E. Luyirika, H. Lyall, E. Malianga, C. Mwansambo, M. Nyathi, F. Miiro, D.M. Gibb, A. Kekitiinwa, P. Mugyenyi, P. Munderi, K.J. Nathoo, A.S. Walker; Observers S. Kinn, M. McNeil, M. Roberts, W. Snowden. ARROW Project Leaders: P. Nahirya-Ntege, S. Bakeera-Kitaka, M. Thomason, M. Bwakura-Dangarembizi, V. Musiime, A.J. Prendergast, P. Musoke.

This work was supported by the National Institutes of Health Office of the Director, Fogarty International Center, Office of AIDS Research, National Cancer Center, National Eye Institute, National Heart, Blood, and Lung Institute, National Institute of Dental and Craniofacial Research, National Institute on Drug Abuse, National Institute of Mental Health, National Institute of Allergy and Infectious Diseases, and National Institutes of Health Office of Women's Health and Research through the Fogarty International Clinical Research Scholars and Fellows Program at Vanderbilt University (R24 TW007988) and the American Relief and Recovery Act. The DART trial was supported by the UK Medical Research Council (MRC; Grant G0600344), the UK Department for International Development (DFID), and the Rockefeller Foundation.

Author Disclosure Statement

GlaxoSmithKline, Gilead Sciences, and Boehringer-Ingelheim donated first-line drugs for DART, and Abbott Laboratories provided lopinavir/ritonavir (Kaletra/Aluvia) as part of the second-line regimen for DART. First line ART in ARROW was provided by GlaxoSmithKline.

References

1. Benoist B, McLean E, Egll I, and Cogswell M: *Worldwide Prevalence of Anaemia 1993–2005: WHO Global Database on Anaemia* (de Benoist B, ed.). World Health Organization, Geneva, Switzerland, 2008.
2. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, and Saag M: Anemia in HIV infection: Clinical impact and evidence-based management strategies. Clin Infect Dis 2004;38(10):1454–1463.
3. Calis JCJ, van Hensbroek MB, de Haan RJ, Moons P, Brabin BJ, and Bates I: HIV-associated anemia in children: A systematic review from a global perspective. AIDS 2008;22(10):1099.
4. Volberding P: Consensus statement: Anemia in HIV infection—current trends, treatment options, and practice strategies. Clin Ther 2000;22(9):1004–1020.
5. Mocroft A, Kirk O, Barton SE, *et al.:* Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS 1999;13(8):943–950.
6. Wisaksana R, Sumantri R, Indrati AR, *et al.:* Anemia and iron homeostasis in a cohort of HIV-infected patients in Indonesia. BMC Infect Dis 2011;11(1):213.
7. O'Brien ME, Kupka R, Msamanga GI, Saathoff E, Hunter DJ, and Fawzi WW: Anemia is an independent predictor of mortality and immunologic progression of disease among women with HIV in Tanzania. J Acquir Immune Defic Syndr 2005;40(2):219–225.
8. Johannessen A, Naman E, Gundersen SG, and Bruun JN: Antiretroviral treatment reverses HIV-associated anemia in rural Tanzania. BMC Infect Dis 2011;11(1):190.
9. Moore RD and Forney D: Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29(1):54.
10. Mildvan D, Creagh T, and Leitz G: Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human-immunodeficiency-virus-infected patients: Findings of the Anemia Prevalence Study. Curr Med Res Opin 2007;23(2):343–355.
11. Owiredu W, Quaye L, N A, and Addai-Mensah O: Prevalence of anaemia and immunological markers among Ghanaian HAART-naive HIV-patients and those on HAART. Afr Health Sci 2011;11(1):2–15.
12. Giganti MJ, Limbada M, Mwango A, *et al.:* Six-month hemoglobin concentration and its association with subsequent mortality among adults on antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 2012;61(1):120–123.
13. Mugyenyi P, Walker A, Hakim J, *et al.:* Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): A randomised non-inferiority trial. Lancet 2010;375(9709):123–131.
14. Kekitiinwa A, Cook A, Nathoo K, *et al.:* Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): A 5-year open-label randomised factorial trial. Lancet 2013;381(9875):1391–1403.
15. WHO: *Antiretroviral Therapy of HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach*. World Health Organization, Geneva, 2006.
16. DART: Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: A randomized double-blind trial (NORA). Trop Med Int Health 2008;13(1):6–16.
17. WHO: *Iron Deficiency Anaemia: Assessment, Prevention and Control: A Guide for Programme Managers.* World Health Organization, Geneva, 2001.
18. Masaisa F, Gahutu JB, Mukiibi J, Delanghe J, and Philippe J: Anemia in human immunodeficiency virus-infected and uninfected women in Rwanda. Am J Trop Med Hyg 2011;84(3):456–460.
19. UNAIDS: 2012 Progress reports submitted by countries. 2012. www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/. Accessed September 11, 2013.
20. Negin J and Cumming RG: HIV infection in older adults in sub-Saharan Africa: Extrapolating prevalence from existing data. Bull World Health Organ 2010;88(11):847–853.
21. High KP, Brennan-Ing M, Clifford DB, *et al.:* HIV and aging: State of knowledge and areas of critical need for research. A Report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 2012;60:S1–S18.
22. Vanasse GJ and Berliner N: Anemia in elderly patients: An emerging problem for the 21st century. Hematology Am Soc Hematol Educ Program 2010;2010(1):271–275.
23. de Pee S and Semba RD: Role of nutrition in HIV infection: Review of evidence for more effective programming in resource-limited settings. Food Nutr Bull 2010;31(Suppl 4):313S–344S.
24. Eley BS, Sive AA, Shuttleworth M, and Hussey GD: A prospective, cross-sectional study of anaemia and peripheral iron status in antiretroviral naive, HIV-1 infected children in Cape Town, South Africa. BMC Infect Dis 2002;2(1):3.
25. Totin D, Ndugwa C, Mmiro F, Perry RT, Jackson JB, and Semba RD: Iron deficiency anemia is highly prevalent among human immunodeficiency virus-infected and uninfected infants in Uganda. J Nutr 2002;132(3):423–429.
26. Shet A, Arumugam K, Rajagopalan N, *et al.:* The prevalence and etiology of anemia among HIV-infected children in India. Eur J Pediatr 2012;171(3):531–540.
27. Obirikorang C and Yeboah FA: Blood haemoglobin measurement as a predictive indicator for the progression of HIV/AIDS in resource-limited setting. J Biomed Sci 2009; 16:102.
28. Ssali F, Stöhr W, Munderi P, *et al.:* Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther 2006;11(6): 741–749.
29. Walker AS, Prendergast AJ, Mugyenyi P, *et al.:* Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis 2012; 55(12):1707–1718.
30. Anude C, Eze E, Onyegbutulem H, *et al.:* Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria. BMC Infect Dis 2013;13(1):113.

31. Labhardt ND, Lejone T, Setoko Ml, *et al.:* A clinical prediction score in addition to WHO criteria for anti-retroviral treatment failure in resource-limited settings—experience from Lesotho. PLoS One 2012;7(10):e47937.
32. Sullivan PS, Hanson DL, and Brooks JT: Impact on hemoglobin of starting combination antiretroviral therapy with or without zidovudine in anemic HIV-infected patients. J Acquir Immune Defic Syndr 2008;48(2): 163–168.
33. Mgogwe J, Semvua H, Msangi R, Mataro C, Kajeguka D, and Chilongola J: The evolution of haematological and biochemical indices in HIV patients during a six-month treatment period. Afr Health Sci 2012;12(1):2–7.
34. WHO: *Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach.* World Health Organization, Geneva, 2013.
35. Munyazesa E, Emile I, Mutimura E, *et al.:* Assessment of haematological parameters in HIV-infected and uninfected Rwandan women: A cross-sectional study. BMJ Open 2012;2(6).
36. Semba RD, Shah N, Klein RS, Mayer KH, Schuman P, and Vlahov D: Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and uninfected women. Clin Infect Dis 2002;34(2):260–266.
37. Levine AM, Berhane K, Masri-Lavine L, *et al.:* Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2001;26(1):28–35.
38. Melekhin VV, Shepherd BE, Stinnette SE, Rebeiro PF, Turner MM, and Sterling TR: Hemoglobin may contribute to sex differences in mortality among HIV-infected persons in care. PLoS One 2012;7(9):e44999.
39. Balarajan Y, Ramakrishnan U, Ozaltin E, Shankar AH, and Subramanian S: Anaemia in low-income and middle-income countries. Lancet 2012;378(9809):2123–2135.
40. Mehta S, Spiegelman D, Aboud S, *et al.:* Lipid-soluble vitamins A, D, and E in HIV-infected pregnant women in Tanzania. Eur J Clin Nutr 2010;64(8):808–817.
41. Kupka R, Msamanga GI, Mugusi F, Petraro P, Hunter DJ, and Fawzi WW: Iron status is an important cause of anemia in HIV-infected Tanzanian women but is not related to accelerated HIV disease progression. J Nutr 2007;137(10):2317–2323.
42. Baltazary G, Akarro R, and Mussa A: Some factors associated with non-adherence to antiretroviral therapy (ART) in people living with HIV/AIDS (PLHA) in Tanzania: A case study of Dar es Salaam region. East Afr J Public Health 2011;8(4):237.
43. Fawzi WW, Msamanga GI, Kupka R, *et al.:* Multivitamin supplementation improves hematologic status in HIV-infected women and their children in Tanzania. Am J Clin Nutr 2007;85(5):1335–1343.
44. Gebo KA: Epidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly. Aging Health 2008;4(6):615–627.
45. Battegay M, Fehr J, Flückiger U, and Elzi L: Antiretroviral therapy of late presenters with advanced HIV disease. J Antimicrob Chemother 2008;62(1):41–44.

Address correspondence to:
Devan Jaganath
David Geffen School of Medicine
University of California, Los Angeles
10833 Le Conte Avenue
Los Angeles, California 90095

E-mail: djaganath@mednet.ucla.edu